Patents Assigned to Vaxart, Inc.
  • Formulations for small intestinal delivery of RSV and norovirus antigens
    Patent number: 12186407
    Abstract: Provided herein are compositions and methods for generating an immunogenic response in humans. Further provided are methods for designing such compositions, e.g., for vaccines.
    Type: Grant
    Filed: August 2, 2022
    Date of Patent: January 7, 2025
    Assignee: Vaxart, Inc.
    Inventors: George Trager, Sean Tucker, Leesun Kim, Ciaran Scallan
  • Formulations for small intestinal delivery of RSV and norovirus antigens
    Patent number: 11433146
    Abstract: Provided herein are compositions and methods for generating an immunogenic response in humans. Further provided are methods for designing such compositions, e.g., for vaccines.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: September 6, 2022
    Assignee: Vaxart, Inc.
    Inventors: George Trager, Sean Tucker, Leesun Kim, Ciaran Scallan
  • FORMULATIONS FOR SMALL INTESTINAL DELIVERY OF RSV AND NOROVIRUS ANTIGENS
    Publication number: 20180161458
    Abstract: Provided herein are compositions and methods for generating an immunogenic response in humans. Further provided are methods for designing such compositions, e.g., for vaccines.
    Type: Application
    Filed: June 8, 2016
    Publication date: June 14, 2018
    Applicant: Vaxart, Inc.
    Inventors: George Trager, Sean Tucker, Leesun Kim, Ciaran Scallan
  • Piperidine derivatives as human papilloma virus inhibitors
    Patent number: 9974779
    Abstract: The present disclosure is directed to antiviral compounds directed against the papilloma virus, to pharmaceutical compositions containing them, to their preparation method and synthesis intermediates, as well as to their use for treating or preventing an infection by the papilloma virus. The present method thus provides an efficient way of treating patients that have lesions associated with an infection by the papilloma virus.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: May 22, 2018
    Assignee: VAXART, INC.
    Inventors: Marta Blumenfeld, Delphine Compere, Jean-Michel Gauthier
  • HSV VACCINES
    Publication number: 20170298389
    Abstract: Provided herein are improved vaccines for HSV-2.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 19, 2017
    Applicant: Vaxart, Inc.
    Inventors: Ciaran Scallan, Wendy Peters
  • FORMULATIONS FOR SMALL INTESTINAL DELIVERY
    Publication number: 20170224805
    Abstract: Provided herein are compositions and methods for generating an immunogenic response in humans. Such compositions include an immunogenic biological agent encompassed by (ii) an agent that directs delivery of the immunogenic biological agent to the ileum of the human, wherein agent (ii) is an enteric coating (e.g., Eudragit®) that has a threshold pH 5.8-6.8. Further provided are methods for designing such compositions, e.g., for vaccines.
    Type: Application
    Filed: February 20, 2015
    Publication date: August 10, 2017
    Applicant: Vaxart, Inc.
    Inventors: Sean Tucker, George Trager
  • Chimeric adenoviral vectors
    Patent number: 8999946
    Abstract: The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: April 7, 2015
    Assignee: Vaxart, Inc.
    Inventor: Sean N. Tucker
  • CHIMERIC ADENOVIRAL VECTORS
    Publication number: 20130164326
    Abstract: The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.
    Type: Application
    Filed: June 25, 2012
    Publication date: June 27, 2013
    Applicant: Vaxart, Inc.
    Inventor: Sean N. Tucker
  • IMMUNIZATION STRATEGY TO PREVENT H1N1 INFECTION
    Publication number: 20120244185
    Abstract: The invention provides chimeric viral expression vectors and method of use for providing an immune response against H1N1 influenza. The compositions of the invention can be used as vaccines for H1N1 strains. Advantages include rapid development and availability once a strain is isolated, and effective oral or mucosal administration.
    Type: Application
    Filed: September 15, 2010
    Publication date: September 27, 2012
    Applicant: Vaxart ,Inc.
    Inventors: Sean N. Tucker, Ciaran Scallan
  • Chimeric adenoviral vectors
    Patent number: 8222224
    Abstract: The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: July 17, 2012
    Assignee: Vaxart, Inc.
    Inventor: Sean N. Tucker
  • CHIMERIC ADENOVIRAL VECTORS
    Publication number: 20110081375
    Abstract: The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.
    Type: Application
    Filed: November 12, 2010
    Publication date: April 7, 2011
    Applicant: Vaxart, Inc.
    Inventor: Sean N. Tucker
  • Chimeric adenoviral vectors
    Patent number: 7879602
    Abstract: The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: February 1, 2011
    Assignee: Vaxart, Inc.
    Inventor: Sean N. Tucker